Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-26

the market expects results and frankly, the quarterly showed little to no improvement from the last 4.

low product revenues from their core product. Lower services revenue and now a longer time frame on their big project with Hologic.

Don’t misunderstand me, this could be a big thing; but the fact is that the mid term is going to be lacklustre at best unless they secure a massive product contract which will be unlikely until clia waiver received.

so further dwindling around 3-4c until clia waiver.

people will shift for short term gains and come back when things are ready to finally move forward.